What is HC Wainwright's Estimate for Arvinas Q1 Earnings?

Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Arvinas in a report issued on Wednesday, February 12th. HC Wainwright analyst A. Fein expects that the company will earn ($0.51) per share for the quarter. HC Wainwright has a "Buy" rating and a $87.00 price target on the stock. The consensus estimate for Arvinas' current full-year earnings is ($3.22) per share. HC Wainwright also issued estimates for Arvinas' Q2 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.56) EPS and FY2029 earnings at $5.28 EPS.

Several other analysts have also recently weighed in on ARVN. Stephens initiated coverage on Arvinas in a report on Monday, November 18th. They issued an "overweight" rating and a $55.00 price target on the stock. Stifel Nicolaus lowered their price target on Arvinas from $63.00 to $51.00 and set a "buy" rating on the stock in a report on Wednesday, February 12th. Oppenheimer raised their price target on Arvinas from $40.00 to $45.00 and gave the company an "outperform" rating in a report on Wednesday, February 12th. BTIG Research initiated coverage on Arvinas in a report on Tuesday, December 10th. They issued a "buy" rating and a $69.00 price target on the stock. Finally, BMO Capital Markets reaffirmed an "outperform" rating and issued a $82.00 price target (down previously from $88.00) on shares of Arvinas in a report on Wednesday, February 12th. Thirteen investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $60.00.

Arvinas Price Performance

Shares of NASDAQ:ARVN traded up $0.32 on Friday, hitting $18.63. The company's stock had a trading volume of 1,789,729 shares, compared to its average volume of 942,180. The company has a 50-day simple moving average of $18.63 and a 200 day simple moving average of $23.05. Arvinas has a 1 year low of $16.61 and a 1 year high of $51.99. The company has a market capitalization of $1.28 billion, a PE ratio of -3.99 and a beta of 1.88.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.44. During the same period in the previous year, the firm posted ($2.53) earnings per share.

Hedge Funds Weigh In On Arvinas

A number of large investors have recently bought and sold shares of ARVN. Exchange Traded Concepts LLC increased its stake in Arvinas by 37.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock worth $164,000 after purchasing an additional 1,798 shares during the period. nVerses Capital LLC purchased a new position in Arvinas in the 3rd quarter worth approximately $39,000. Assenagon Asset Management S.A. purchased a new position in Arvinas in the 3rd quarter worth approximately $3,442,000. E. Ohman J or Asset Management AB increased its stake in Arvinas by 20.1% in the 3rd quarter. E. Ohman J or Asset Management AB now owns 29,830 shares of the company's stock worth $735,000 after purchasing an additional 5,000 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Arvinas by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company's stock worth $61,000 after purchasing an additional 440 shares during the period. 95.19% of the stock is owned by hedge funds and other institutional investors.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.